The research group for cancer immunotherapy is composed of representatives from clinical departments and research institutes at Oslo University Hospital.
The group’s main objective is to work for the initiation and completion of clinical trials within immunotherapy, multicenter studies in immunotherapy and translational research related to these studies.
Immunotherapy and especially cancer vaccines need to be developed and enhanced to a greater degree to become an important modality in addition to current standard therapies such as surgery, radiotherapy and chemotherapy. In order to succeed with this, a close cooperation between basic research and clinicians is highly important, which will allow conduction clinical trials based on translational research.
The group has extensive national and international collaboration. It’s research activity spans from translational basal research, to pre-clinical studies and clinical studies.
Early phase drug development: From idea to concept
Feb 3, 2017
Feb 2, 2017
Oncolytic peptide LTX-315; the road from basic science to clinical trials
Jan 26, 2017